Experimental drug cocktail takes on childhood brain cancers
NCT ID NCT07567469
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests two immunotherapy drugs, fianlimab and cemiplimab, in children and young adults with recurrent high-grade glioma or ependymoma. The goal is to see if the combination is safe and can shrink tumors or slow their growth. Participants will receive the drugs before and after surgery to remove their tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fianlimab and cemiplimab (immunotherapy drugs)
What this could lead to
If successful, this could offer a new treatment option for children and young adults with recurrent brain tumors that are hard to treat.
What could go wrong
This is an early-phase trial (phase 1/2) with a small number of participants. The drugs may cause side effects or not work for everyone. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE GLIOMA (HGG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••